Management of hepatocellular carcinoma

Michael A. Choti

Research output: Contribution to journalArticle

Abstract

Hepatocellular carcinoma (HCC) is responsible for a significant amount of morbidity and mortality throughout the world. In many countries, including the United States, a definite increase in the incidence of HCC has been reported recently, largely attributable to the increasing incidence of hepatitis C infection. Unfortunately, the current management of HCC is confusing due to the large number of treatment options available. The difficulty of managing a patient with HCC is compounded by the lack of well-designed, randomized clinical trials comparing the various treatment modalities. Nevertheless, many exciting management options are currently available that may prove valuable in the treatment of this disease. Partial hepatic resection or, in some instances, liver transplantation offers the best chance for cure. However, various ablative therapies, including percutaneous ethanol injection, radiofrequency ablation, and cryosurgery, may produce a survival benefit. In the future, systemic chemotherapy and transarterial chemoembolization, employed either alone or as adjuncts to ablation or resection, may play an increasing role in palliating or down-staging a patient with advanced HCC. This overview of the state-of-the-art management of HCC attempts to guide the practicing physician in selecting the best treatment plan for an individual with HCC.

Original languageEnglish (US)
Pages (from-to)1085-1098
Number of pages14
JournalOncology
Volume14
Issue number7
StatePublished - 2000

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Cryosurgery
Incidence
Hepatitis C
Liver Transplantation
Ethanol
Randomized Controlled Trials
Morbidity
Physicians
Drug Therapy
Injections
Survival
Mortality
Liver
Infection

ASJC Scopus subject areas

  • Oncology

Cite this

Choti, M. A. (2000). Management of hepatocellular carcinoma. Oncology, 14(7), 1085-1098.

Management of hepatocellular carcinoma. / Choti, Michael A.

In: Oncology, Vol. 14, No. 7, 2000, p. 1085-1098.

Research output: Contribution to journalArticle

Choti, MA 2000, 'Management of hepatocellular carcinoma', Oncology, vol. 14, no. 7, pp. 1085-1098.
Choti MA. Management of hepatocellular carcinoma. Oncology. 2000;14(7):1085-1098.
Choti, Michael A. / Management of hepatocellular carcinoma. In: Oncology. 2000 ; Vol. 14, No. 7. pp. 1085-1098.
@article{bee48256b73247508fe82c03b5eb5ef7,
title = "Management of hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is responsible for a significant amount of morbidity and mortality throughout the world. In many countries, including the United States, a definite increase in the incidence of HCC has been reported recently, largely attributable to the increasing incidence of hepatitis C infection. Unfortunately, the current management of HCC is confusing due to the large number of treatment options available. The difficulty of managing a patient with HCC is compounded by the lack of well-designed, randomized clinical trials comparing the various treatment modalities. Nevertheless, many exciting management options are currently available that may prove valuable in the treatment of this disease. Partial hepatic resection or, in some instances, liver transplantation offers the best chance for cure. However, various ablative therapies, including percutaneous ethanol injection, radiofrequency ablation, and cryosurgery, may produce a survival benefit. In the future, systemic chemotherapy and transarterial chemoembolization, employed either alone or as adjuncts to ablation or resection, may play an increasing role in palliating or down-staging a patient with advanced HCC. This overview of the state-of-the-art management of HCC attempts to guide the practicing physician in selecting the best treatment plan for an individual with HCC.",
author = "Choti, {Michael A.}",
year = "2000",
language = "English (US)",
volume = "14",
pages = "1085--1098",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7",

}

TY - JOUR

T1 - Management of hepatocellular carcinoma

AU - Choti, Michael A.

PY - 2000

Y1 - 2000

N2 - Hepatocellular carcinoma (HCC) is responsible for a significant amount of morbidity and mortality throughout the world. In many countries, including the United States, a definite increase in the incidence of HCC has been reported recently, largely attributable to the increasing incidence of hepatitis C infection. Unfortunately, the current management of HCC is confusing due to the large number of treatment options available. The difficulty of managing a patient with HCC is compounded by the lack of well-designed, randomized clinical trials comparing the various treatment modalities. Nevertheless, many exciting management options are currently available that may prove valuable in the treatment of this disease. Partial hepatic resection or, in some instances, liver transplantation offers the best chance for cure. However, various ablative therapies, including percutaneous ethanol injection, radiofrequency ablation, and cryosurgery, may produce a survival benefit. In the future, systemic chemotherapy and transarterial chemoembolization, employed either alone or as adjuncts to ablation or resection, may play an increasing role in palliating or down-staging a patient with advanced HCC. This overview of the state-of-the-art management of HCC attempts to guide the practicing physician in selecting the best treatment plan for an individual with HCC.

AB - Hepatocellular carcinoma (HCC) is responsible for a significant amount of morbidity and mortality throughout the world. In many countries, including the United States, a definite increase in the incidence of HCC has been reported recently, largely attributable to the increasing incidence of hepatitis C infection. Unfortunately, the current management of HCC is confusing due to the large number of treatment options available. The difficulty of managing a patient with HCC is compounded by the lack of well-designed, randomized clinical trials comparing the various treatment modalities. Nevertheless, many exciting management options are currently available that may prove valuable in the treatment of this disease. Partial hepatic resection or, in some instances, liver transplantation offers the best chance for cure. However, various ablative therapies, including percutaneous ethanol injection, radiofrequency ablation, and cryosurgery, may produce a survival benefit. In the future, systemic chemotherapy and transarterial chemoembolization, employed either alone or as adjuncts to ablation or resection, may play an increasing role in palliating or down-staging a patient with advanced HCC. This overview of the state-of-the-art management of HCC attempts to guide the practicing physician in selecting the best treatment plan for an individual with HCC.

UR - http://www.scopus.com/inward/record.url?scp=0034223661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034223661&partnerID=8YFLogxK

M3 - Article

C2 - 10929592

AN - SCOPUS:0034223661

VL - 14

SP - 1085

EP - 1098

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7

ER -